Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335303 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13242621 | 0.90 | CA12 (0.50) | MAPTMEN1KMT2AGSK3BMAOB | |
| SCHEMBL2997666 | 0.87 | KDM4E (0.58) | MAPTKMT2ANPC1RAB9AGSK3B | |
| SCHEMBL2997672 | 0.87 | KDM4E (0.58) | MAPTKMT2ANPC1RAB9AGSK3B | |
| SCHEMBL13242546 | 0.85 | CA12 (0.58) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13704175 | 0.85 | BACE1 (0.53) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL4322780 | 0.85 | KMT2A (0.49) | MAPTMEN1KMT2ABACE1LMNA | |
| SCHEMBL4330721 | 0.85 | KMT2A (0.49) | MAPTMEN1KMT2ABACE1LMNA | |
| SCHEMBL4328627 | 0.83 | MMP1 (0.66) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2995205 | 0.83 | TTR (0.54) | MAPTMEN1KMT2AEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| EP-1709155-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | PYGL, TP53, MKI67 | MAPT 2994/4885MEN1 1240/4885KMT2A 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.